{"entity":{"id":"errfi1","kind":"target","name":"ERRFI1","aka":["ERBB receptor feedback inhibitor 1","MIG-6","GENE-33"],"tldr":"ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.","summary":"Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 4 variants, naming Erlotinib and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18185","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18185"},{"label":"UniProt Q9UJM3","url":"https://www.uniprot.org/uniprotkb/Q9UJM3/entry"},{"label":"NCBI Gene 54206","url":"https://www.ncbi.nlm.nih.gov/gene/54206"},{"label":"Ensembl ENSG00000116285","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116285"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["cholangiocarcinoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ERRFI1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:18185","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18185","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UJM3","url":"https://www.uniprot.org/uniprotkb/Q9UJM3/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ERRFI1","url":"https://civicdb.org/features/12271","note":"2 evidence items, 0 assertions, 4 variants; diseases: Cholangiocarcinoma, Lung Non-small Cell Carcinoma (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ERRFI1: RNA tissue enhanced (liver 695 nTPM, pancreas 640 nTPM); blood lineage lineage enriched (monocytes 2 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Biliary tract cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ERRFI1 tissue","url":"https://www.proteinatlas.org/ENSG00000116285-ERRFI1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000116285 associations","url":"https://platform.opentargets.org/target/ENSG00000116285/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:18185","ensembl":"ENSG00000116285","uniprot":"Q9UJM3","entrez":"54206","firstDescribed":1995,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Wick et al, Exp. Cell Res, 1995, \"Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7641805/","biology":"Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation. Inhibits autophosphorylation of EGFR, ERBB2 and ERBB4. Important for normal keratinocyte proliferation and differentiation. Plays a role in modulating the response to steroid hormones in the uterus. Location: Cytoplasm; Cell membrane; Nucleus (UniProt). Locus 1p36.23 (HGNC).","whereFound":["Biliary tract cancer: CIViC evidence names this disease","Non-small-cell lung cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/errfi1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}